miR-425-5p在子宫内膜癌患者血清和组织中的表达及预后
|
摘要
目的:检测微小RNA-425-5p(miR-425-5p)在子宫内膜癌患者血清和组织中的表达及与预后关系。方法:收集本院2014年4月—2015年5月收治的子宫内膜癌患者84例为研究对象,另取健康体检妇女50例为健康对照组。qRT-PCR检测受试者血清及患者癌组织和癌旁组织中miR-425-5p表达水平。结果:子宫内膜癌患者血清miR-425-5p表达水平高于对照组,癌组织中表达水平高于癌旁正常组织(均P<0.05);血清和组织中miR-425-5p表达水平与子宫内膜癌肿瘤分期、淋巴结转移和分化程度有关,低表达患者总生存率高于高表达患者(均P<0.05)。COX分析表明,血清和组织中miR-425-5p表达水平、组织分化程度是影响子宫内膜癌患者预后的独立危险因素(P<0.05)。结论:miR-425-5p在子宫内膜癌患者血清和组织中表达均上调,且与患者预后有关,可作为子宫内膜癌患者预后评判的参考指标。
Objective: To detect the expression of micro RNA-425-5 p(miR-425-5 p) in serum and tissues of patients with endometrial carcinoma, and to explore the relationships between different expression levels with prognosis of patients. Methods: 84 patients with endometrial carcinoma were selected in study group from April 2014 to May 2015, and 50 healthy women were selected in control group. QRT-PCR was used to detect the expression of miR-425-5 p in the serum, cancer tissues, and adjacent tissues of patients. Results: The serum level of miR-425-5 p of patients in study group was significant higher than that of patients in control group(P<0.05).The expression of miR-425-5 p in endometrial carcinoma tissues was significant higher than that in adjacent normal tissues(P <0.05). The expression of miR-425-5 p in serum and tissues was correlated to the tumor stage, lymph node metastasis and differentiation(P<0.05). The overall survival rate of patients with low miR425-5 p expression in serum and tissues was significant higher than that of patients with low miR425-5 p expression(P<0.05). COX analysis showed that the expression of miR-425-5 p in serum and tissues, and the degree of tissue differentiation were independent risk factors for the prognosis of patients(P<0.05). Conclusion: The expressions of MiR-425-5 p in serum and tissues up-regulate, which is related to the prognosis of patients, so it can be used as reference index for prognosis assessment.
Objective: To detect the expression of micro RNA-425-5 p(miR-425-5 p) in serum and tissues of patients with endometrial carcinoma, and to explore the relationships between different expression levels with prognosis of patients. Methods: 84 patients with endometrial carcinoma were selected in study group from April 2014 to May 2015, and 50 healthy women were selected in control group. QRT-PCR was used to detect the expression of miR-425-5 p in the serum, cancer tissues, and adjacent tissues of patients. Results: The serum level of miR-425-5 p of patients in study group was significant higher than that of patients in control group(P<0.05).The expression of miR-425-5 p in endometrial carcinoma tissues was significant higher than that in adjacent normal tissues(P <0.05). The expression of miR-425-5 p in serum and tissues was correlated to the tumor stage, lymph node metastasis and differentiation(P<0.05). The overall survival rate of patients with low miR425-5 p expression in serum and tissues was significant higher than that of patients with low miR425-5 p expression(P<0.05). COX analysis showed that the expression of miR-425-5 p in serum and tissues, and the degree of tissue differentiation were independent risk factors for the prognosis of patients(P<0.05). Conclusion: The expressions of MiR-425-5 p in serum and tissues up-regulate, which is related to the prognosis of patients, so it can be used as reference index for prognosis assessment.
引文
[1] Goebel E, Vidal A, Matias G, et al. The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future [J]. Virchows Arch, 2018, 472(6):885-896.
[2] Burke W, Orr J, Leitao M, et al. Endometrial cancer: a review and current management strategies: part II [J]. Gynecol Oncol, 2014, 134(2):393-402.
[3] Ma G, Liu Z. Reflection on micro RNAs in cancer: the next decade [J]. Science Bulletin, 2015, 60(24):1-3.
[4] Gao Y, Yin Y, Xing X, et al. Arsenic-induced anti-angiogenesis via miR-425-5p- regulated CCM3 [J]. Toxicol Lett, 2016, 254(1):22-31.
[5] 蔡洲,戴宇罖.miRNA-425-5p促进胰腺癌细胞增殖、迁移与侵袭过程的分子机制 [J].中国老年学杂志,2017,37(11):2629-2631.
[6] Zhang Z, Wen M, Guo J, et al. Clinical value of miR-425-5p detection and its association with cell proliferation and apoptosis of gastric cancer [J]. Pathol Res Pract, 2017, 213(8):929-937.
[7] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志.2018,34(8):880-886.
[8] 周莹, 冯凤芝, 金滢,等. 子宫内膜增生并发子宫内膜癌的高危因素及预后分析[J]. 实用妇产科杂志, 2016, 32(11):826-829.
[9] 夏玲芳, 吴小华. 子宫内膜癌的手术治疗[J]. 中国实用妇科与产科杂志, 2017, 33(5):461-465.
[10] Bracken C, Scott H, Goodall G. A network-biology perspective of microRNA function and dysfunction in cancer [J]. Nat Rev Genet, 2016, 17(12):719-732.
[11] Huang K, Tang Y, He L, et al. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway [J]. Oncol Rep, 2016, 35(2):887-95.
[12] Zhang W, Liu J, Qiu J, et al. MicroRNA-382 inhibits prostate cancer cell proliferation and metastasis through targeting COUP-TFII [J]. Oncol Rep. 2016, 36(6):3707-3715.
[13] Zhang Y, Wen X, Hu XL, et al. Downregulation of miR-145-5p correlates with poor prognosis in gastric cancer [J]. Eur Rev Med Pharmacol Sci, 2016 , 20(14): 3026-3030.
[14] Wang Z, Ma X, Cai Q, et al. MiR-199a-3p promotes gastric cancer progression by targeting ZHX1 [J]. Febs Letters, 2016, 588(23):4504-4512.
[15] Wan H, Li Q, Zhang Y, et al. miR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells [J]. Cancer Lett. 2014, 355(1):148-158.
[16] 底建敏,王梵,赵欢,等.miR-183在子宫内膜癌Ishikawa细胞中的表达及其对p53蛋白的调节作用[J].中国妇幼保健,2016,31(24):5476-5479.
[17] Sun L, Jiang R, Li J, et al. MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer[J]. Ann Clin Biochem, 2017, 54(1):127-133.
[18] 孔繁菲,马剑,丛蓉,等.miR-497-5p在子宫内膜病变组织中的表达及临床意义[J].中国医科大学学报,2018,47(7):593-596+600.
[2] Burke W, Orr J, Leitao M, et al. Endometrial cancer: a review and current management strategies: part II [J]. Gynecol Oncol, 2014, 134(2):393-402.
[3] Ma G, Liu Z. Reflection on micro RNAs in cancer: the next decade [J]. Science Bulletin, 2015, 60(24):1-3.
[4] Gao Y, Yin Y, Xing X, et al. Arsenic-induced anti-angiogenesis via miR-425-5p- regulated CCM3 [J]. Toxicol Lett, 2016, 254(1):22-31.
[5] 蔡洲,戴宇罖.miRNA-425-5p促进胰腺癌细胞增殖、迁移与侵袭过程的分子机制 [J].中国老年学杂志,2017,37(11):2629-2631.
[6] Zhang Z, Wen M, Guo J, et al. Clinical value of miR-425-5p detection and its association with cell proliferation and apoptosis of gastric cancer [J]. Pathol Res Pract, 2017, 213(8):929-937.
[7] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志.2018,34(8):880-886.
[8] 周莹, 冯凤芝, 金滢,等. 子宫内膜增生并发子宫内膜癌的高危因素及预后分析[J]. 实用妇产科杂志, 2016, 32(11):826-829.
[9] 夏玲芳, 吴小华. 子宫内膜癌的手术治疗[J]. 中国实用妇科与产科杂志, 2017, 33(5):461-465.
[10] Bracken C, Scott H, Goodall G. A network-biology perspective of microRNA function and dysfunction in cancer [J]. Nat Rev Genet, 2016, 17(12):719-732.
[11] Huang K, Tang Y, He L, et al. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway [J]. Oncol Rep, 2016, 35(2):887-95.
[12] Zhang W, Liu J, Qiu J, et al. MicroRNA-382 inhibits prostate cancer cell proliferation and metastasis through targeting COUP-TFII [J]. Oncol Rep. 2016, 36(6):3707-3715.
[13] Zhang Y, Wen X, Hu XL, et al. Downregulation of miR-145-5p correlates with poor prognosis in gastric cancer [J]. Eur Rev Med Pharmacol Sci, 2016 , 20(14): 3026-3030.
[14] Wang Z, Ma X, Cai Q, et al. MiR-199a-3p promotes gastric cancer progression by targeting ZHX1 [J]. Febs Letters, 2016, 588(23):4504-4512.
[15] Wan H, Li Q, Zhang Y, et al. miR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells [J]. Cancer Lett. 2014, 355(1):148-158.
[16] 底建敏,王梵,赵欢,等.miR-183在子宫内膜癌Ishikawa细胞中的表达及其对p53蛋白的调节作用[J].中国妇幼保健,2016,31(24):5476-5479.
[17] Sun L, Jiang R, Li J, et al. MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer[J]. Ann Clin Biochem, 2017, 54(1):127-133.
[18] 孔繁菲,马剑,丛蓉,等.miR-497-5p在子宫内膜病变组织中的表达及临床意义[J].中国医科大学学报,2018,47(7):593-596+600.